Zhejiang Hisun Pharmaceutical's acarbose patent application in the United States is currently under examination. The application, U.S. Patent Application No. 16/642,983, was filed on February 27, 2018, and published on September 3, 2020 [1].
What is Acarbose and How Does it Work?
Acarbose is an oral anti-diabetic drug belonging to the alpha-glucosidase inhibitor class. It works by slowing down the digestion of carbohydrates in the small intestine, thereby reducing the rapid rise in blood glucose levels after meals. This mechanism helps to manage hyperglycemia in individuals with type 2 diabetes [2].
What is the Status of Drug Patents for Acarbose?
The patent landscape for acarbose is complex due to its established history as a medication. While the original patents for acarbose may have expired, companies often seek new patents for specific formulations, manufacturing processes, or methods of use. Zhejiang Hisun Pharmaceutical's application suggests ongoing efforts to secure intellectual property related to acarbose in the U.S. market [1]. Information on specific patent expirations for acarbose can be found through resources like DrugPatentWatch.com [3].
Why Would a Company File a New Patent Application for an Existing Drug?
Companies may file new patent applications for existing drugs for several strategic reasons. This can include protecting novel manufacturing methods that improve efficiency or purity, developing new formulations with enhanced bioavailability or patient compliance, or identifying and patenting new therapeutic uses for the drug. Such applications aim to extend market exclusivity or create barriers for competitors [4].
What is the Expected Timeline for Patent Application Review?
The timeline for reviewing a U.S. patent application can vary significantly depending on the complexity of the invention and the workload of the U.S. Patent and Trademark Office (USPTO). Typically, it can take anywhere from a few months to several years from the filing date to a final decision. Zhejiang Hisun's application, filed in 2018, is still within a timeframe where it would be undergoing examination [1].
What Are the Implications of Patent Approval for Zhejiang Hisun?
If Zhejiang Hisun's patent application is approved, it could grant them exclusive rights to the claimed invention related to acarbose in the United States. This exclusivity would prevent other companies from making, using, selling, or importing the patented subject matter without authorization, potentially impacting the competitive landscape for acarbose in the U.S. market [4].
Who Else Manufactures Acarbose?
Acarbose is manufactured by several pharmaceutical companies globally. In the United States, generic versions of acarbose are available from various manufacturers. The market for acarbose includes both branded and generic products [2].
What Are the Next Steps in the Patent Application Process?
Following the initial examination, the USPTO may issue an office action detailing any objections or rejections to the claims in the patent application. Zhejiang Hisun would then have the opportunity to respond to these office actions by amending the claims or providing arguments to overcome the rejections. This back-and-forth process continues until the application is either allowed or finally rejected [1].
Sources:
[1] United States Patent Application Publication US 2020/0276115 A1
[2] National Institute of Diabetes and Digestive and Kidney Diseases. (n.d.). Acarbose.
[3] DrugPatentWatch.com
[4] U.S. Patent and Trademark Office. (n.d.). Patent Basics.